MICROBIOLOGY DEPARTMENT UPDATE

• SUSCEPTIBILITIES TO CEFTAROLINE (TEFLARO) WITH E-TEST

• NEW GRAM NEGATIVE PANEL, AST-GN92

Ceftaroline susceptibility with E-Test
(for treatment of Staphylococcus aureus and MRSA).
Test run by request only. Susceptibility Interpretive Criteria for Ceftaroline:

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>MIC (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S</td>
</tr>
<tr>
<td>Staphylococcus aureus (includes methicillin-resistant isolates only)*</td>
<td>≤ 1</td>
</tr>
</tbody>
</table>

a. The current absence of resistant isolates precludes defining any results other than "susceptible."

New gram negative panel, AST-GN2
Reporting of the new gram negative panel will begin once our supply of the old panel is depleted (approximately 2 weeks). This new panel was assembled in consultation with Infectious Disease and Pharmacy, AST-GN92 panel:

- Amikacin
- Ampicillin
- Ampicillin/Sulbactam
- Aztreonam
- Cefazolin
- Ceftazidime
- Cefotaxin
- Ceftriaxone
- ESBL Confirmatory
- Gentamicin
- Imipenem
- Levofloxacin
- Meropenem
- Nitrofurantoin
- Piperacillin/Tazobactam
- Tobramycin
- Trimethoprim-Sulfamethoxazole

If you have any questions or comments regarding these changes do not hesitate to contact Ana Maria Mazziotti, CLS, Microbiology Supervisor (818-847-6074), Vivian Chantakrivat, CLS, Manager Technical Operations (818-847-6078) or Kathleen Makarewicz, MD, Medical Director Clinical Laboratory Services (818-847-6053).